Claims

1. A liquid formulation comprising:
   a) an anti-Transthyretin antibody,
   b) a buffer,
   c) a sugar,
   d) L-Arginine,
   e) L-Methionine and
   f) a surfactant, and
   wherein the pH of the formulation is within the range from 5.0-7.0.

2. The formulation according to claim 1 comprising:
   a) 20-250 mg/mL anti-Transthyretin antibody,
   b) 10-50 mM histidine,
   c) 20-200 mM sucrose,
   d) 50-300 mM L-Arginine,
   e) 5-50 mM L-Methionine and
   f) 0.2-5.0 mg/mL surfactant.

3. The formulation according to claim 1 or claim 2, wherein the surfactant is Poloxamer 188 (PX188), Polysorbate 80 (PS80) or Polysorbate 20 (PS20).

4. The formulation according to any of the preceding claims, wherein the formulation is essentially free of sodium chloride.

5. The formulation according to any of the preceding claims, wherein the formulation comprises 40-60 mM sucrose.

6. The formulation according to any of the preceding claims, wherein the surfactant is PX188 and wherein the concentration of PX188 is 0.2-2.0 mg/mL, such as 0.2-1.5 mg/mL, 0.3-1.4 mg/mL or 0.4-1.2 mg/mL such as about 0.2, 0.4 or 1.0 mg/mL.

7. The formulations according to any one of the preceding claims, wherein Methionine is present at a concentration of 10-50 mM L-Methionine, such as 10-45 mM, 15-45 mM, 15-

40 mM, 15-35 mM, 15-30 mM or 15-25 mM Methionine and wherein Arginine is present at a concentration of 50-150 mM, such as 75-125 mM L-Arginine.

8. The formulation according to any of the preceding claims, wherein the formulation comprises about 20 mM L-histidine, about 50 mM sucrose, about 100 mM L-Arginine, about 20 mM L-Methionine and 1.0 mg/mL PX188.

9. The formulations according to any of the preceding claims, wherein the anti-Transthyretin antibody comprises
   i. a heavy chain variable region comprising complementarity determining regions (CDRs) wherein CDR1 is SEQ ID NO.: 1, CDR2 is SEQ ID NO.: 2 or 3 and CDR3 is SEQ ID NO.: 4 and
   ii. a light chain variable region comprising complementarity determining regions (CDRs) wherein CDR1 is SEQ ID NO.: 5 or 6, CDR2 is SEQ ID NO.: 7 and CDR3 is SEQ ID NO.: 8.

10. The formulation according to any of the preceding claims, wherein the anti-Transthyretin antibody comprises a heavy chain variable region comprising amino acid sequence of SEQ ID NO.: 10, and a light chain variable region comprising amino acid sequence of SEQ ID NO.: 14.

11. The formulation according to any of the preceding claims, wherein the anti-Transthyretin antibody comprises a heavy chain comprising amino acid sequence of SEQ ID NO.: 15 and a light chain comprising amino acid sequence of SEQ ID NO.: 16.

12. The formulation according to any of the preceding claims, wherein the anti-Transthyretin antibody is present at a concentration of 40-180 mg/mL, such as about 50, 100, or 150 mg/mL.

13. The formulation according to any of the preceding claims, wherein the pH is about 5.5-6.5, 5.8-6.2 or about 6.0.

14. A liquid formulation, wherein the formulation comprises

a) about 50-150 mg/mL of an antibody comprising three heavy chain CDRs and three light chain CDRs, wherein the three heavy chain CDRs are SEQ ID NOs 1, 2 and 4, respectively and wherein the three light chain CDRs are SEQ ID NOs 6, 7 and 8 respectively,

b) a histidine buffer at a concentration of about 20 mM;

c) sucrose at a concentration of about 50 mM;

d) poloxamer, such as PX188, at a concentration of about 0.1%;

e) about 100 mM L-Arginine;

f) about 20 mM L-Methionine

and has a pH of about 6.0.

15. The formulation according to any of the preceding claims, where in the formulation is an aqueous pharmaceutical formulation.